当前位置:首页 / 乙型肝炎相关性肝硬化患者血清circMTO1表达水平及其与肝纤维化程度、预后的相关性
论著·临床研究 | 更新时间:2024-05-09
|
乙型肝炎相关性肝硬化患者血清circMTO1表达水平及其与肝纤维化程度、预后的相关性
Expression of serum circMTO1 in patients with hepatitis B associated cirrhosis and its correlation with degree of liver fibrosis and prognosis

广西医学 页码:255-259

作者机构:兰莹,硕士,副主任技师,研究方向为微生物检验。

基金信息:四川省疾病预防控制中心自立科研课题(ZX201906)

DOI:10.11675/j.issn.0253⁃4304.2024.02.13

  • 中文简介
  • 英文简介
  • 参考文献

目的 分析乙型肝炎相关性肝硬化患者血清环状RNA线粒体tRNA翻译优化因子1(circMTO1)表达水平及其与肝纤维化程度、预后的关系。方法 纳入115例乙型肝炎相关性肝硬化患者(乙肝肝硬化组)及120例慢性乙型肝炎患者(慢乙肝组)作为研究对象。根据治疗后短期预后情况,将乙肝肝硬化组患者分为预后良好组(n=84)与预后不良组(n=31)。比较乙肝肝硬化组与慢乙肝组之间、预后良好组与预后不良组之间的血清circMTO1表达水平。分析乙肝肝硬化组血清circMTO1表达水平与肝纤维化分级的相关性。采用受试者工作特征曲线分析血清circMTO1表达水平对乙肝肝硬化组患者不良预后的预测价值。结果 乙肝肝硬化组患者的血清circMTO1表达水平低于慢乙肝组,预后不良组患者的circMTO1表达水平低于预后良好组(P<0.05)。乙肝肝硬化组患者血清circMTO1表达水平与肝纤维化分级呈负相关(P<0.05)。血清circMTO1表达水平预测乙肝肝硬化组患者预后不良的曲线下面积为0.747,敏感度为77.40%,特异度为77.40%,最佳截断值为0.332。结论 与未发生肝硬化的慢性乙型肝炎患者相比,乙型肝炎相关性肝硬化患者的血清circMTO1表达水平降低,且其与肝纤维化程度相关。circMTO1或可作为评估乙型肝炎相关性肝硬化患者预后的分子标志物。

Objective To analyze the expression of serum circular RNA mitochondrial tRNA translation optimization 1 (circMTO1) in patients with hepatitis B associated cirrhosis and its relation with the degree of liver fibrosis and prognosis. Methods A total of 115 patients with hepatitis B associated cirrhosis (the hepatitis B cirrhosis group) and 120 patients with chronic hepatitis B (the chronic hepatitis B group) were enrolled as the research subjects. Patients in the hepatitis B cirrhosis group were assigned to favorable prognosis group (n=84) or adverse prognosis group (n=31) according to short⁃term prognosis after treatment. Serum circMTO1 expression was compared between the hepatitis B cirrhosis group and the chronic hepatitis B group, and between the favorable prognosis group and the adverse prognosis group. The correlation of serum circMTO1 expression with classification of liver fibrosis was analyzed in the hepatitis B cirrhosis group. The receiver operating characteristic curve was used to analyze the predictive value of serum circMTO1 expression on adverse prognosis in patients of the hepatitis B cirrhosis group. Results Patients in the hepatitis B cirrhosis group obtained a lower serum circMTO1 expression as compared with the chronic hepatitis B group, and serum circMTO1 expression was lower in the adverse prognosis group than in the favorable prognosis group (P<0.05). Serum circMTO1 expression negatively correlated with classification of liver fibrosis in patients of the hepatitis B cirrhosis group (P<0.05). Area under the curve of serum circMTO1 expression for predicting adverse prognosis in patients of the hepatitis B cirrhosis group was 0.747, the sensitivity was 77.40%, the specificity was 77.40%, and the optimal cut-off value was 0.332. Conclusion Compared with chronic hepatitis B patients without suffering from cirrhosis, patients with hepatitis B associated cirrhosis obtain a decreased serum circMTO1 expression, and it is related to the degree of liver fibrosis. Prognosis of patients with hepatitis B associated cirrhosis can be evaluated by circMTO1, which can be regarded as a molecular marker. 

  • ref
  • ref
  • ref
  • ref
  • ref
  • ref
  • ref
  • ref
  • ref
  • ref
  • ref
  • ref
  • ref
  • ref
  • ref
  • ref
  • ref

89

浏览量

10

下载量

0

CSCD

工具集